XAIR
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Beyond Air, Inc. (XAIR) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (F). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | B (3.3) | C- (2.0) | F (0.6) | C+ (2.6) | C (2.3) |
| 2026-11-08 | B- (3.0) | B (3.3) | C- (2.0) | F (0.7) | C+ (2.6) | C (2.3) |
| 2026-11-01 | B- (3.0) | B (3.3) | C- (2.1) | F (0.6) | C+ (2.7) | C (2.3) |
| 2026-10-25 | B- (3.0) | B (3.3) | C- (2.1) | F (0.6) | C+ (2.6) | C (2.3) |
| 2026-10-18 | B- (3.0) | B (3.3) | C- (2.1) | F (0.6) | C+ (2.6) | C (2.3) |